Preprint The German Multicenter Registry for ME/CFS MECFS-R, 2024, Hieber, Scheibenbogen, Behrends et al.

Discussion in 'ME/CFS research' started by SNT Gatchaman, Apr 28, 2024.

  1. SNT Gatchaman

    SNT Gatchaman Senior Member (Voting Rights)

    Messages:
    4,874
    Location:
    Aotearoa New Zealand
    The German Multicenter Registry for ME/CFS MECFS-R
    Hannah Hieber; Rafael Pricoco; Katrin Gerrer; Cornelia Heindrich; Katharina Wiehler; Lorenz L Mihatsch; Matthias Haegele; Daniela Schindler; Quirin Donath; Catharina Christa; Annika Grabbe; Alissa Kircher; Ariane Leone; Yvonne Mueller; Hannah Zietemann; Helma Freitag; Franzisky Sotzny; Cordula Warlitz; Silvia Stojanov; Anna Hausruckinger; Kirstin Mittelstrass; Daniel Hattesohl; Carmen Scheibenbogen; Uta Behrends

    Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating multi-systemic disease characterized by a complex, incompletely understood etiology. To facilitate future clinical and translational research, a multicenter German ME/CFS registry was established to collect comprehensive, longitudinal, clinical, epidemiological, and laboratory data from adults, adolescents, and children in a web-based multilayer-secured database.

    Here, we present the research protocol and first results of a pilot cohort of 174 ME/CFS patients diagnosed at two specialized tertiary fatigue centers, including 130 (74.7%) adults (mean age 38.4; SD 12.6) and 43 (25.3%) pediatric patients (mean age 15.5; SD 4.2). A viral trigger was identified in 160/174 (92.0%) cases, with SARS-CoV-2 in almost half of them.

    Patients exhibited severe functional and social impairment, as reflected by a median Bell Score of 30.0 (IQR 30.0 to 40.0) and a poor health-related quality of life assessed with the Short form-36 health survey, resulting in a mean score of 40.4 (SD 20.6) for physical function and 59.1 (SD 18.8) for mental health.

    The MECFS-R provides important clinical information on ME/CFS to research and healthcare institutions and, together with a multicenter ME/CFS biobank, will pave the way for research projects addressing the pathogenesis, diagnostic markers, and treatment options.

    TRIAL REGISTRATION
    ClinicalTrials.gov NCT05778006.


    Link | PDF (Preprint: MedRxiv) [Open Access]
     
    Deanne NZ, Joh, tmrw and 4 others like this.
  2. Hutan

    Hutan Moderator Staff Member

    Messages:
    27,828
    Location:
    Aotearoa New Zealand
    I thought the introduction of this paper was very well written. Of course I have quibbles - I guess that goes without saying - (e.g. the description of PEM) but it seemed like a nice summary of the disease and a justification for a patient registry in 8 or so paragraphs.
     
  3. Hutan

    Hutan Moderator Staff Member

    Messages:
    27,828
    Location:
    Aotearoa New Zealand
    Interesting finding on the utility of the DSQ-PEM:
     
  4. Hutan

    Hutan Moderator Staff Member

    Messages:
    27,828
    Location:
    Aotearoa New Zealand
    acute disease at onset - 82/174 had a confirmed trigger of SARS-CoV-2
    useful data
     
    Deanne NZ, lycaena, tmrw and 5 others like this.
  5. Hutan

    Hutan Moderator Staff Member

    Messages:
    27,828
    Location:
    Aotearoa New Zealand
    Justification for the registry. Of note is the relationship with clinics, so that there probably is reduced bias (or at least a different bias) in the people who are included in the registry, compared to situations where registry participation is more the result of participants hearing about the registry on social media or from patient charities. Participants have clinically confirmed disease.

     
    Deanne NZ, lycaena, tmrw and 6 others like this.
  6. John Mac

    John Mac Senior Member (Voting Rights)

    Messages:
    958

Share This Page